OBJECTIVE: To describe the prevalence of atrial fibrillation (AF) in patients with rheumatoid arthritis (RA), and to evaluate the proportion of patients with AF receiving guideline-recommended anticoagulation for prevention of stroke, based on data from a large international audit. METHODS: The cohort was derived from the international audit SUrvey of cardiovascular disease Risk Factors in patients with Rheumatoid Arthritis (SURF-RA) which collected data from 17 countries during 2014-2019. We evaluated the prevalence of AF across world regions and explored factors associated with the presence of AF with multivariable logistic regression models. The proportion of AF patients at high risk of stroke (CHA2DS2-VASc ≥ 2 in males and ≥ 3 in females) receiving anticoagulation was examined. RESULTS: Of the total SURF-RA cohort (n = 14,503), we included RA cases with data on whether the diagnosis of AF was present or not (n = 7,665, 75.1% women, mean (SD) age 58.7 (14.1) years). A total of 288 (3.8%) patients had a history of AF (4.4% in North America, 3.4% in Western Europe, 2.8% in Central and Eastern Europe and 1.5% in Asia). Factors associated with the presence of AF were older age, male sex, atherosclerotic cardiovascular disease, heart failure and hypertension. Two-hundred and fifty-five (88.5%) RA patients had a CHA2DS2-VASc score indicating recommendation for oral anticoagulant treatment, and of them, 164 (64.3%) were anticoagulated. CONCLUSION: Guideline-recommended anticoagulant therapy for prevention of stroke due to AF may not be optimally implemented among RA patients, and requires special attention.

• Klíčová slova
• Anticoagulation, Atrial fibrillation, Pharmacotherapy, Rheumatoid arthritis,
• Publikační typ
• časopisecké články MeSH

AIMS: To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). METHODS AND RESULTS: The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014-19. The treatment goal for BP was <140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. CONCLUSION: We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.

• Klíčová slova
• Audit, Blood pressure, Lipids, Prevention, Rheumatoid arthritis, Statins,
• MeSH
• dyslipidemie * diagnóza   farmakoterapie   epidemiologie   MeSH
• hypertenze * diagnóza   farmakoterapie   epidemiologie   MeSH
• kardiovaskulární nemoci * diagnóza   epidemiologie   prevence a kontrola   MeSH
• lidé MeSH
• lipidy MeSH
• revmatoidní artritida * diagnóza   farmakoterapie   epidemiologie   MeSH
• rizikové faktory MeSH
• statiny * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• lipidy MeSH
• statiny * MeSH

OBJECTIVE: To examine whether all-cause hospitalization rates for patients with rheumatoid arthritis (RA) differ from those for patients without RA. PATIENTS AND METHODS: This was a retrospective population-based cohort study focused on Olmsted County, Minnesota. The RA cohort consisted of patients 18 years and older who first fulfilled 1987 American College of Rheumatology criteria for RA in the 1980 to 2007 period, and was compared with a cohort of similar age, sex, and calendar year without RA. Data on all hospitalizations were retrieved electronically for the 1987 to 2012 period. Analyses used person-year methods and rate ratios (RRs) comparing patients with and without RA. RESULTS: The 799 patients with RA experienced 2968 hospitalizations, and the 797 patients without RA experienced 2069 hospitalizations. Patients with RA were hospitalized at a greater rate than were patients without RA (RR, 1.51; 95% CI, 1.42-1.59). This increased rate of hospitalization was found in both sexes, all age groups, all calendar years studied, and throughout disease duration. Men with RA were hospitalized for depression at a greater rate than were men without RA (RR, 7.16; 95% CI, 2.78-30.67). Patients with RA were hospitalized at a greater rate for diabetes mellitus than were subjects without RA (RR, 2.45; 95% CI, 1.34-4.89). In patients with RA, the indicators of disease severity (eg, seropositivity, erosions, and nodules) in the first year after RA incidence were associated with higher rates of hospitalization. CONCLUSION: Patients with RA were hospitalized for all causes at a greater rate than were patients without RA. Increased rates of hospitalization were true for several disease categories and patient subgroups.

• MeSH
• dospělí MeSH
• hospitalizace statistika a číselné údaje   MeSH
• incidence MeSH
• kohortové studie MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• retrospektivní studie MeSH
• revmatoidní artritida epidemiologie   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Research Support, N.I.H., Extramural MeSH
• Geografické názvy
• Minnesota epidemiologie   MeSH